IMMUSOFT CORP
Genetically engineered autologous human B cells that produce therapeutic IDS protein via Sleeping Beauty transposon-mediated gene transfer for in vivo enzyme replacement in lysosomal storage diseases
- Sector
- Biotech
- Headquarters
- Seattle, WA
- Latest Form D
- $4.6M, Jun 2024
- Total capital
- $25.9M
- Federal grants
- $8.1M
- 5 awards · 2018–2020
- Rank in peer group#227 of 514
- Private capital raised
- $17.8M
- 6 Form D · last Jun 2024
- 28 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 29 pending · first 2019
- Rank in peer group#109 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$4.6M
- Federal grantHealth and Human S · Phase I · Transposon Engineered B Cell Therapy for Hunter Syndrome$467K
- Federal grantHealth and Human S · Phase I · Transposon Engineered B Cell Therapy for Hunter Syndrome$467K
- Private capital raisedForm D · SEC · 5th filing$4.1M
- Federal grantHealth and Human S · Phase II · Sleeping Beauty Engineered B Cells for Mucopolysaccharidosis$2.6M
- Federal grantHealth and Human S · Phase II · Sleeping Beauty Engineered B Cells for Mucopolysaccharidosis$3.6M
- Federal grantHealth and Human S · Phase II · Sleeping Beauty Engineered B Cells for Mucopolysaccharidosis$1M
- Private capital raisedForm D · SEC · 4th filing$3.6M
- Private capital raisedForm D · SEC · 3rd filing$2.7M
- Private capital raisedForm D · SEC · 2nd filing$375K
- Private capital raisedForm D · SEC · 1st filing$2.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#227 · top 44%
- Granted patents#109 · top 21%
- Linked publications#20 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Scott McIvorResearcherExecutive OfficerLinked by 1 patent
- Anthony SunDirectorNamed in SEC Form D filings
- Cam GallahgerDirectorNamed in SEC Form D filings
- Eric GarciaExecutive OfficerNamed in SEC Form D filings
- Eric HerbigExecutive OfficerNamed in SEC Form D filings
- Julia c/o MooreDirectorNamed in SEC Form D filings
Show all 12 people
- Mark Ahn, Ph.D.DirectorNamed in SEC Form D filings
- Matthew ScholzExecutive Officer, DirectorNamed in SEC Form D filings
- Richard Chin, M.D.DirectorNamed in SEC Form D filings
- Rich VincentExecutive OfficerNamed in SEC Form D filings
- Sean AinsworthExecutive Officer, DirectorNamed in SEC Form D filings
- Wendell KingDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 32- PendingMethods For In Vitro Memory B Cell Differentiation And Transduction With Vsv-g Pseudotyped Viral VectorsUSPTOApplication 19028976
- PendingMigratory Modified Differentiated B Cells For Cancer TherapyUSPTOApplication 18949362
- PendingMethods Of Administering Genetically Modified B Cells For In Vivo Delivery Of Therapeutic AgentsUSPTOApplication 18034865
Show all 32 patent records
- Methods For In Vitro Memory B Cell Differentiation And Transduction With Vsv-g Pseudotyped Viral VectorsJul 31, 2025 · Application 19028976Pending
- Migratory Modified Differentiated B Cells For Cancer TherapyMay 15, 2025 · Application 18949362Pending
- Methods Of Administering Genetically Modified B Cells For In Vivo Delivery Of Therapeutic AgentsDec 28, 2023 · Application 18034865Pending
- B Cells For In Vivo Delivery Of Therapeutic AgentsMar 16, 2023 · Application 17886337Pending
- Methods For In Vitro Memory B Cell Differentiation And Transduction With Vsv-g Pseudotyped Viral VectorsJan 19, 2023 · Application 17735676Pending
- B Cells For In Vivo Delivery Of Therapeutic Agents And Dosages ThereofJun 23, 2022 · Application 16607962Pending
- Methods For In Vitro Memory B Cell Differentiation And Transduction With Vsv-g Pseudotyped Viral VectorsJun 7, 2022 · US 11,352,603Granted
- Method To Achieve Extended Expression Of Dna Infused Into LiverAug 31, 2021 · US 11,103,582Granted
- B Cells Genetically Engineered To Secrete Follistatin And Methods Of Using The Same To Treat Follistatin-related Diseases, Conditions, Disorders And To Enhance Muscle Growth And StrengthFeb 18, 2021 · Application 16981618Pending
- Chimeric Antigen Receptors Specific To AVB6 Integrin And Methods Of Use Thereof To Treat CancerMay 21, 2020 · Application 16431592Pending
- Methods For In Vitro Memory B Cell Differentiation And Transduction With Vsv-g Pseudotyped Viral VectorsMar 26, 2019 · US 10,240,125Granted
- B Cells For In Vivo Delivery Of Therapeutic AgentsJan 4, 2018 · Application 15537334Pending
- Method To Achieve Extended Expression Of Dna Infused Into LiverMay 22, 2014 · Application 14083931Pending
- B Cells For In Vivo Delivery Of Therapeutic AgentsApplication PCTUS2015066908Pending
- B Cells For In Vivo Delivery Of Therapeutic AgentsApplication 62110063Pending
- B Cells For In Vivo Delivery Of Therapeutic AgentsApplication 62094794Pending
- Methods For In Vitro Memory B Cell Differentiation And Transduction With Vsv-g Pseudotyped Viral VectorsApplication PCTUS2014027910Pending
- Vectors And Methods For Transducing B CellsApplication PCTUS2011020578Pending
- B Cell Compositions And Methods Of UseApplication PCTUS2025050889Pending
- GLP-1 Expressing Modified B Cells For The Treatment Of Metabolic DiseaseApplication 19603559Pending
- GLP-1 Expressing Modified B Cells For The Treatment Of Metabolic DiseaseApplication PCTUS2025010182Pending
- Migratory Modified Differentiated B Cells For Cancer TherapyApplication PCTUS2024056186Pending
- B Cell Compositions And Methods Of UseApplication 63707106Pending
- GLP-1 Expressing Recombinant B Cells For The Treatment Of Metabolic DiseaseApplication 63617992Pending
- Migratory Modified B Cells For Cancer TherapyApplication 63599102Pending
- Methods Of Administering Genetically Modified B Cells For In Vivo Delivery Of Therapeutic AgentsApplication PCTUS2021057363Pending
- Methods Of Administering Genetically Modified B Cells For In Vivo Delivery Of Therapeutic AgentsApplication 63107992Pending
- B Cells Genetically Engineered To Secrete Follistatin And Methods Of Using The Same To Treat Follistatin-related Diseases, Conditions, Disorders And To Enhance Muscle Growth And StrengthApplication PCTUS2019022821Pending
- B Cells For In Vivo Delivery Of Therapeutic Agents And Dosages ThereofApplication PCTUS2018029993Pending
- B Cells Genetically Engineered To Secrete Follistatin And Methods Of Using The Same To Treat Follistatin-related Diseases, Conditions, Disorders And To Enhance Muscle Growth And StrengthApplication 62644356Pending
- B Cells Genetically Engineered To Secrete Follistatin And Methods Of Using The Same To Treat Follistatin-related Diseases, Conditions, Disorders And To Enhance Muscle Growth And StrengthApplication 62644362Pending
- B Cells For In Vivo Delivery Of Therapeutic Agents And Dosages ThereofApplication 62491151Pending
Recent research by its founders
- Dataset for 'GBA1 deficiency differentially affects endolysosomal trafficking in neurons versus astrocytes'20260 cites
- <i>GBA1</i> deficiency differentially affects endolysosomal trafficking in neurons versus astrocytes20260 cites
- Smoking, GAD65 autoimmunity, genetic susceptibility to type 1 diabetes and incident adult-onset diabetes in the EPIC-InterAct case–cohort study20260 cites
Related companies, and why
- Glycobac, LLCSimilar federal contract value in Biotech · null in contracts
- ZENOPHARM, LLCSimilar federal contract value in Biotech · null in contracts
- OMNIOX INCSimilar federal contract value in Biotech · null in contracts
- DARE BIOSCIENCE, INC.Similar federal contract value in Biotech · null in contracts
- Ventus TherapeuticsSimilar federal contract value in Biotech · null in contracts
- TFF PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .